LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 145

Search options

  1. Article ; Online: Culex modestus: the overlooked mosquito vector.

    Soto, Alina / Delang, Leen

    Parasites & vectors

    2023  Volume 16, Issue 1, Page(s) 373

    Abstract: Culex (Barraudius) modestus (Ficalbi 1889) are found in temperate regions across Europe, Asia, and Northern Africa. These mosquitoes thrive during the summer and prefer to breed in permanent vegetative habitats such as rice paddies and marshes. Culex ... ...

    Abstract Culex (Barraudius) modestus (Ficalbi 1889) are found in temperate regions across Europe, Asia, and Northern Africa. These mosquitoes thrive during the summer and prefer to breed in permanent vegetative habitats such as rice paddies and marshes. Culex modestus feed on a wide range of bird species but are highly attracted to humans, which makes them a potential 'bridge' vector for enzootic pathogens. There is compelling evidence that Culex modestus is an efficient vector for West Nile virus, potentially capable of causing epidemics in humans and other mammals. This species is also a likely vector for Usutu virus, avian malaria (Plasmodium spp.), and parasitic heartworms (Dirofilaria spp.). Culex modestus can be morphologically identified at the larval and adult stages, and a distinctive phenotype of this species is their ability to overwinter. Despite the widespread establishment of this mosquito species and their role as vectors for human pathogens, we lack sufficient knowledge on this species to implement and evaluate targeted vector control measures. Since Culex modestus can be considered a potential public health threat, there is a need for a better understanding of this mosquito species.
    MeSH term(s) Animals ; Humans ; Culex ; Mosquito Vectors ; Insect Vectors ; Plant Breeding ; Culicidae ; West Nile virus ; Mammals
    Language English
    Publishing date 2023-10-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2409480-8
    ISSN 1756-3305 ; 1756-3305
    ISSN (online) 1756-3305
    ISSN 1756-3305
    DOI 10.1186/s13071-023-05997-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Antiviral Strategies against Arthritogenic Alphaviruses.

    Abdelnabi, Rana / Delang, Leen

    Microorganisms

    2020  Volume 8, Issue 9

    Abstract: Alphaviruses are members of ... ...

    Abstract Alphaviruses are members of the
    Language English
    Publishing date 2020-09-07
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms8091365
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: β-D-N

    Rosales-Rosas, Ana Lucia / Soto, Alina / Wang, Lanjiao / Mols, Raf / Fontaine, Albin / Sanon, Aboubakar / Augustijns, Patrick / Delang, Leen

    Antiviral research

    2024  Volume 225, Page(s) 105858

    Abstract: Chikungunya virus (CHIKV) is a mosquito-borne virus transmitted by Aedes mosquitoes. While there are no antiviral therapies currently available to treat CHIKV infections, several licensed oral drugs have shown significant anti-CHIKV activity in cells and ...

    Abstract Chikungunya virus (CHIKV) is a mosquito-borne virus transmitted by Aedes mosquitoes. While there are no antiviral therapies currently available to treat CHIKV infections, several licensed oral drugs have shown significant anti-CHIKV activity in cells and in mouse models. However, the efficacy in mosquitoes has not yet been assessed. Such cross-species antiviral activity could be favorable, since virus inhibition in the mosquito vector might prevent further transmission to vertebrate hosts. Here, we explored the antiviral effect of β-d-N
    MeSH term(s) Animals ; Mice ; Chikungunya virus/physiology ; Chikungunya Fever ; Aedes ; Virus Replication ; Antiviral Agents ; Cytidine/analogs & derivatives
    Chemical Substances N(4)-hydroxycytidine (C3D11PV2O4) ; Antiviral Agents ; Cytidine (5CSZ8459RP)
    Language English
    Publishing date 2024-03-13
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2024.105858
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Medical treatment options for COVID-19.

    Delang, Leen / Neyts, Johan

    European heart journal. Acute cardiovascular care

    2020  Volume 9, Issue 3, Page(s) 209–214

    Abstract: Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus ... ...

    Abstract Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019.
    MeSH term(s) Adenosine Monophosphate/administration & dosage ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/pharmacology ; Adenosine Monophosphate/therapeutic use ; Administration, Intravenous ; Alanine/administration & dosage ; Alanine/analogs & derivatives ; Alanine/pharmacology ; Alanine/therapeutic use ; Amides/pharmacology ; Amides/therapeutic use ; Antibodies, Monoclonal, Humanized/pharmacology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antiviral Agents/administration & dosage ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; COVID-19 ; Chloroquine/adverse effects ; Chloroquine/toxicity ; Clinical Trials as Topic ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Cytochrome P-450 CYP3A Inhibitors/therapeutic use ; Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage ; Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology ; Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use ; Humans ; Immunologic Factors/therapeutic use ; Lopinavir/pharmacology ; Lopinavir/therapeutic use ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; RNA, Viral/drug effects ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/pharmacology ; Recombinant Proteins/therapeutic use ; SARS-CoV-2
    Chemical Substances Amides ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Cytochrome P-450 CYP3A Inhibitors ; Immunologic Factors ; Pyrazines ; RNA, Viral ; Recombinant Proteins ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; sargramostim (5TAA004E22) ; Granulocyte-Macrophage Colony-Stimulating Factor (83869-56-1) ; Chloroquine (886U3H6UFF) ; favipiravir (EW5GL2X7E0) ; tocilizumab (I031V2H011) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-05-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2663340-1
    ISSN 2048-8734 ; 2048-8726
    ISSN (online) 2048-8734
    ISSN 2048-8726
    DOI 10.1177/2048872620922790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Tarsal exposure to atovaquone inhibits chikungunya virus transmission by Aedes aegypti mosquitoes, but not the transmission of Zika virus.

    Wang, Lanjiao / Sanon, Aboubakar / Khoiriyah, Zakiyatul / Verwimp, Sam / Abdelnabi, Rana / Delang, Leen

    Antiviral research

    2023  Volume 217, Page(s) 105694

    Abstract: The antimalarial drug atovaquone was recently reported to inhibit the in vitro replication of different arboviruses, including chikungunya virus (CHIKV) and Zika virus (ZIKV). Furthermore, atovaquone was shown to block Plasmodium parasite transmission by ...

    Abstract The antimalarial drug atovaquone was recently reported to inhibit the in vitro replication of different arboviruses, including chikungunya virus (CHIKV) and Zika virus (ZIKV). Furthermore, atovaquone was shown to block Plasmodium parasite transmission by Anopheles mosquitoes when the mosquitoes were exposed to low concentrations on treated surfaces (i.e. tarsal exposure). Therefore, we evaluated the anti-CHIKV and -ZIKV effects of atovaquone via tarsal exposure in Aedes aegypti mosquitoes. We first confirmed that atovaquone exerted a dose-dependent antiviral effect on CHIKV and ZIKV replication in mosquito-derived cells. The modest antiviral effect could be rescued by adding exogenous uridine. Next, we assessed the effect of tarsal exposure to atovaquone on the fitness of Ae. aegypti. Concentrations up to 100 μmol/m
    MeSH term(s) Animals ; Female ; Zika Virus ; Chikungunya virus ; Aedes ; Zika Virus Infection ; Atovaquone ; Mosquito Vectors ; Chikungunya Fever ; Antiviral Agents/pharmacology
    Chemical Substances Atovaquone (Y883P1Z2LT) ; Antiviral Agents
    Language English
    Publishing date 2023-08-01
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2023.105694
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Repurposing Drugs for Mayaro Virus: Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors.

    Langendries, Lana / Abdelnabi, Rana / Neyts, Johan / Delang, Leen

    Microorganisms

    2021  Volume 9, Issue 4

    Abstract: Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus. Here, we optimized a robust antiviral assay based on the inhibition of ... ...

    Abstract Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus. Here, we optimized a robust antiviral assay based on the inhibition of the cytopathogenic effect that could be used for high-throughput screening to identify MAYV inhibitors. We first evaluated different cell lines and virus inputs to determine the best conditions for a reliable and reproducible antiviral assay. Next, we used this assay to evaluate a panel of antiviral compounds with known activity against other arboviruses. Only three drugs were identified as inhibitors of MAYV: β-D-N
    Language English
    Publishing date 2021-03-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720891-6
    ISSN 2076-2607
    ISSN 2076-2607
    DOI 10.3390/microorganisms9040734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Antiviral Strategies against Arthritogenic Alphaviruses

    Rana Abdelnabi / Leen Delang

    Microorganisms, Vol 8, Iss 1365, p

    2020  Volume 1365

    Abstract: Alphaviruses are members of the Togaviridae family that are mainly transmitted by arthropods such as mosquitoes. In the last decades, several alphaviruses have re-emerged, causing outbreaks worldwide. One example is the re-emergence of chikungunya virus ( ...

    Abstract Alphaviruses are members of the Togaviridae family that are mainly transmitted by arthropods such as mosquitoes. In the last decades, several alphaviruses have re-emerged, causing outbreaks worldwide. One example is the re-emergence of chikungunya virus (CHIKV) in 2004, which caused massive epidemics in the Indian Ocean region after which the virus dramatically spread to the Americas in late 2013. Besides CHIKV, other alphaviruses, such as the Ross River virus (RRV), Mayaro virus (MAYV), and Venezuelan equine encephalitis virus (VEEV), have emerged and have become a serious public health concern in recent years. Infections with the Old World alphaviruses (e.g., CHIKV, RRV) are primarily associated with polyarthritis and myalgia that can persist for months to years. On the other hand, New World alphaviruses such as VEEV cause mainly neurological disease. Despite the worldwide (re-)emergence of these viruses, there are no antivirals or vaccines available for the treatment or prevention of infections with alphaviruses. It is therefore of utmost importance to develop antiviral strategies against these viruses. We here provided an overview of the reported antiviral strategies against arthritogenic alphaviruses. In addition, we highlighted the future perspectives for the development and the proper use of such antivirals.
    Keywords arbovirus ; alphavirus ; chikungunya ; antivirals ; capping ; protease ; Biology (General) ; QH301-705.5
    Language English
    Publishing date 2020-09-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Repurposing Drugs for Mayaro Virus

    Lana Langendries / Rana Abdelnabi / Johan Neyts / Leen Delang

    Microorganisms, Vol 9, Iss 734, p

    Identification of EIDD-1931, Favipiravir and Suramin as Mayaro Virus Inhibitors

    2021  Volume 734

    Abstract: Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus. Here, we optimized a robust antiviral assay based on the inhibition of ... ...

    Abstract Despite the emerging threat of the Mayaro virus (MAYV) in Central and South-America, there are no licensed antivirals or vaccines available for this neglected mosquito-borne virus. Here, we optimized a robust antiviral assay based on the inhibition of the cytopathogenic effect that could be used for high-throughput screening to identify MAYV inhibitors. We first evaluated different cell lines and virus inputs to determine the best conditions for a reliable and reproducible antiviral assay. Next, we used this assay to evaluate a panel of antiviral compounds with known activity against other arboviruses. Only three drugs were identified as inhibitors of MAYV: β-D-N 4 -hydroxycytidine (EIDD-1931), favipiravir and suramin. The in vitro anti-MAYV activity of these antiviral compounds was further confirmed in a virus yield assay. These antivirals can therefore serve as reference compounds for future anti-MAYV compound testing. In addition, it is of interest to further explore the activity of EIDD-1931 and its orally bioavailable pro-drug molnupiravir in animal infection models to determine whether it offers promise for the treatment of MAYV infection.
    Keywords Mayaro virus ; antivirals ; alphaviruses ; emerging viruses ; Biology (General) ; QH301-705.5
    Language English
    Publishing date 2021-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Medical treatment options for COVID-19

    Delang, Leen / Neyts, Johan

    European Heart Journal: Acute Cardiovascular Care

    2020  Volume 9, Issue 3, Page(s) 209–214

    Abstract: Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus ... ...

    Abstract Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019.
    Keywords Critical Care and Intensive Care Medicine ; Cardiology and Cardiovascular Medicine ; General Medicine ; covid19
    Language English
    Publisher SAGE Publications
    Publishing country us
    Document type Article ; Online
    ZDB-ID 2663340-1
    ISSN 2048-8734 ; 2048-8726
    ISSN (online) 2048-8734
    ISSN 2048-8726
    DOI 10.1177/2048872620922790
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article: Medical treatment options for COVID-19

    Delang, Leen / Neyts, Johan

    Eur Heart J Acute Cardiovasc Care

    Abstract: Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus ... ...

    Abstract Therapeutic options for coronavirus disease 2019 are desperately needed to respond to the ongoing severe acute respiratory syndrome coronavirus 2 pandemic. Both antiviral drugs and immunomodulators might have their place in the management of coronavirus disease 2019. Unfortunately, no drugs have been approved yet to treat infections with human coronaviruses. As it will take years to develop new therapies for severe acute respiratory syndrome coronavirus 2, the current focus is on the repurposing of drugs that have been approved or are in development for other conditions. Several clinical trials have already been conducted or are currently ongoing to evaluate the efficacy of such drugs. Here, we discuss the potential of these therapies for the treatment of coronavirus disease 2019.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #165340
    Database COVID19

    Kategorien

To top